share_log

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com

由StockNews.com分析师发起的Genocea Biosciences（纳斯达克股票代码：GNCA
Defense World ·  2022/07/16 02:41

StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report released on Saturday. The brokerage set a "sell" rating on the biotechnology company's stock.

斯托克新闻网在周六发布的一份报告中开始报道基因生物科学公司(纳斯达克代码：GNCA-GET评级)的股票。该经纪公司对这家生物技术公司的股票设定了“卖出”评级。

A number of other equities research analysts have also weighed in on GNCA. Robert W. Baird decreased their target price on Genocea Biosciences from $8.00 to $3.00 in a research report on Monday, April 11th. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Finally, Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research report on Friday, April 29th.

其他一些股票研究分析师也加入了对GNCA的看法。罗伯特·W·贝尔德在4月11日星期一的一份研究报告中将他们对Genocea Biosciences的目标价从8.00美元下调至3.00美元。在4月29日星期五发布的一份研究报告中，HC Wainwright将Genocea Biosciences的评级从买入下调至中性。最后，Stifel Nicolaus在4月29日星期五的一份研究报告中将Genocea Biosciences的评级从“买入”下调至“持有”。

Get
到达
Genocea Biosciences
Genocea生物科学
alerts:
警报：

Genocea Biosciences Stock Performance

Genocea Bioscions股票表现

Shares of NASDAQ GNCA opened at $0.02 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. The business has a fifty day simple moving average of $0.07 and a two-hundred day simple moving average of $0.64. The firm has a market cap of $881,010.00, a PE ratio of -0.02 and a beta of 2.26. Genocea Biosciences has a twelve month low of $0.01 and a twelve month high of $2.24.

上周五，纳斯达克大中华区的股价开盘报0.02美元。该公司的速动比率为1.35，流动比率为1.35，债务权益比为0.24。该业务的50日简单移动均线切入位为0.07美元，200日简单移动均线切入位为0.64美元。该公司市值为881,010.00美元，市盈率为-0.02，贝塔系数为2.26。Genocea Biosciences的12个月低点为0.01美元，12个月高位为2.24美元。

Insider Transactions at Genocea Biosciences

Genocea Biosciences的内幕交易

In other news, Director Ali Behbahani sold 4,445,093 shares of the business's stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Ali Behbahani sold 4,445,093 shares of the business's stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total value of $415,229.01. Following the completion of the transaction, the insider now directly owns 4,445,093 shares of the company's stock, valued at $311,156.51. The disclosure for this sale can be found here. In the last three months, insiders sold 10,537,612 shares of company stock valued at $781,461. Corporate insiders own 1.61% of the company's stock.
在其他新闻方面，董事Ali贝赫巴哈尼在5月25日(星期三)的一笔交易中出售了4445,093股该公司的股票。这只股票的平均售价为0.08美元，总价值为355,607.44美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个超级链接获得。在其他新闻方面，董事Ali贝赫巴哈尼在5月25日(星期三)的一笔交易中出售了4445,093股该公司的股票。这只股票的平均售价为0.08美元，总价值为355,607.44美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过这个超级链接获得。此外，大股东保罗·爱德华·沃克在5月24日星期二的一次交易中出售了5931,843股该公司的股票。这只股票的平均售价为0.07美元，总价值为415,229.01美元。交易完成后，这位内部人士现在直接拥有该公司4,445,093股股票，价值311,156.51美元。此次拍卖的披露信息可在此处找到。在过去的三个月里，内部人士出售了10,537,612股公司股票，价值781,461美元。企业内部人士持有该公司1.61%的股份。

Institutional Inflows and Outflows

机构资金流入和流出

A hedge fund recently bought a new stake in Genocea Biosciences stock. Acadian Asset Management LLC bought a new stake in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 21,741 shares of the biotechnology company's stock, valued at approximately $25,000. Hedge funds and other institutional investors own 59.25% of the company's stock.

一家对冲基金最近购买了Genocea Biosciences股票的新股份。根据Acadian Asset Management LLC向美国证券交易委员会(Securities And Exchange Commission)的最新披露，该公司在第四季度购买了Genocea Biosciences，Inc.(纳斯达克代码：GNCA-GET Rating)的新股。该机构投资者买入了这家生物技术公司21,741股股票，价值约25,000美元。对冲基金和其他机构投资者持有该公司59.25%的股票。

About Genocea Biosciences

关于Genocea生物科学

(Get Rating)

(获取评级)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
  • MarketBeat: Week in Review 7/11 – 7/15
  • Is Coupang's Stock On The Verge Of A Turnaround?
  • Should You Have These Two Banks In Your Portfolio?
  • Verint Systems Stock is a Customer Engagement Play
  • Why Shopify Stock Split...And is as Shoppable as Ever
  • 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
  • MarketBeat：回顾一周7/11-7/15
  • Coupang的股票即将翻身吗？
  • 你的投资组合中应该有这两家银行吗？
  • Verint Systems Stock是一场客户互动活动
  • 为什么Shopify股票拆分...并一如既往地适合购物

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发